Edward Zissman, MD, FAAP
AAP

INDUSTRY GOALS AND PROGRESS FOR VACCINE BARCODING - PERSPECTIVE FROM AAP

"Reviewed April 2013"
Automated Identification of Vaccine Products

Process and Partnerships to Improve Patient Safety and Office Efficiency

Presentation to the CDC
January 26, 2012
Edward N Zissman, MD, FAAP
Co-chair AAP Ad-hoc Committee on AIVP
I have the following disclosures:

- Consultant to RTI
- Merck Customer Solutions Advisory Board Member
- Clinical Research principal investigator:
  
  a. Merck Vaccine Study
  b. Novartis Vaccine Study
  c. Mead Johnson Formula Study
  d. Sanofi-Pasteur Vaccine Study
  e. Med-Immune RSV Study
  f. GSK Vaccine Study
  g. B-D Strep Test Study
Immunizations and the AAP

- Pediatricians provide a majority of immunizations in the US
- Both vaccine safety and financing issues have been priorities for the Academy
- The Committee on Infectious Diseases writes immunization recommendations
- The Committee on Practice and Ambulatory Medicine deals with practice implementation issues
Bar-coding and the AAP

- Several pediatricians in practice and AAP leadership were interested in implementing bar coding on immunization vials and syringes
- Primary drivers:
  - Rapid uptake of technology
  - Vaccine safety and reporting of adverse events
  - Increased need for office efficiency
- AAP started to investigate feasibility
AAP Process: Learn History

- Discuss history with CDC and manufacturers
  - Gather previous bar coding experiences
  - Identify why desired outcome was not achieved
  - Learn from past leaders, create contacts with key movers and shakers
2004
Vaccine Identification Standards Initiative Begins

2006
Bar-coding Rule Implemented

2007-08
Environment Changes

2009
AAP Convenes Stakeholders

February 2, 2010
Meeting with FDA
AAP Process: Identify Stakeholders

Originally included:

- Medical associations (AAP, AAFP, AMA, etc)
- Manufacturers
- CDC
- FDA
- Public health
  - ASTHO, [Association of State and Territorial Health Officials]
  - AIM [Association for Automatic Identification and Mobility]
- Standards group GS1
- AIRA [American Immunization Registry Association]

Think broadly:

- Distributors
- Pharmacies
- Pharma
- NVPO [National Vaccine Program Office]
- EHR and PMS Vendors
AAP Process:
Jan. 2009 Gather Information

- Convened stakeholders from government, public health, manufacturers and pediatricians to discuss feasibility and barriers
  - Bar coding Technology is ready but vials and syringes must have 2D barcodes to include GTIN, lot number, and expiration date to be useful to practices at the point of vaccine administration
  - Linear bar code on such a small vial or syringe cannot include sufficient information

- Because of concurrent serialization efforts, primary focus was unit dose, not packaging
AAP Process: Address Barriers

- Need permission from FDA - 2004 guidance dictated the use of linear barcodes
- AAP was identified as the lead for communications with FDA
- AAP, manufacturers, and GS1 met with FDA in February 2010 to discuss allowing 2D codes on the unit dose of vaccines
- With no major objections, FDA issued updated guidance in September 2010
Public comments were taken on the updated guidance
  ▸ New stakeholders were identified
  ▸ While guidance was positive and a step in the right direction, finalization of guidance took 11 months and certain public comments are still to be addressed
AAP Process: Develop Guidelines

- AAP provides a forum for industry competitors to discuss common issues with special attention to anti-trust laws
- Partnerships with standards groups and those using technology at the point of care are needed
Guidance is needed for uniform implementation by manufacturers.

Guidance is also needed for offices, registries, EMRs, etc.

Two guidance manuals for 2D bar coding have been published by the AAP in collaboration with GS-1:
- The manufacturer’s guidance
- The clinician’s guidance
Number of recommended vaccines has increased

Since 2004, several new vaccines (rotavirus, human papillomavirus, hepatitis A, MCV4 and 1 additional dose (varicella) have been added to the schedule.

Influenza vaccine recommendations were also expanded to include children up to 18 years.

Several combination products have been introduced (e.g., DTaP-IPV-HIB, DTaP-IPV-HebB)
Time to record data has increased

National Childhood Vaccine Injury Act of 1986 requires recording of:

- Vaccine identity (i.e., manufacturer and product), date administered, lot number, VIS information, and provider identity
  - CDC has announced plan to place 2D bar code on the VIS
- AAP also recommends site, route, and expiration date
### IMMUNIZATION ADMINISTRATION CHART - CHILD

**Clinic Name/Address:**

**PATIENT'S SOCIAL SECURITY NO.:**

**MOTHER'S SOCIAL SECURITY NO.:**

**ADDRESS:**

**MOTHER'S MAIDEN NAME:**

**TELEPHONE NUMBER:**

**CITY:**

**STATE:**

**ZIP:**

**I.D. NUMBER:**

I agree to allow the health care provider giving vaccinations to release information about all vaccinations given to me, or to the person for whom I am authorized to consent, to the Kansas Immunization Information System (KIIS), other health care providers and schools in order to avoid receiving unnecessary vaccinations and to provide information about what immunizations have been received. I understand that I am not required to agree to the release of this information in order to receive the vaccinations I request.

I have read or have had explained to me the information contained in the Vaccine Information Statements (VIS's) about the following disease(s) and vaccine(s): Polio, Diphtheria, Tetanus, Pertussis, Measles, Mumps, Rubella, Haemophilus Influenza type b, Hepatitis B, Hepatitis A, Varicella, Pneumococcal conjugate, and Influenza. I have had a chance to ask questions that were answered to my satisfaction. I understand the benefits and risks of the vaccine(s) and request that the vaccine(s) indicated on this form be given to me or the person named on this health record for whom I am authorized to make this request.

<table>
<thead>
<tr>
<th>VACCINE (CIRCLE WHAT IS GIVEN)</th>
<th>DATE SHOT &amp; VIS GIVEN</th>
<th>SIGNATURE OF RECIPIENT OF VACCINE OR PERSON AUTHORIZED TO REQUEST</th>
<th>VACCINE MANUF.</th>
<th>VACCINE LOT NO.</th>
<th>EXP DATE</th>
<th>SITE GIVEN</th>
<th>NAME/TITLE OF VACCINE ADMINISTRATOR</th>
<th>VIS PUB DATE</th>
<th>VFC CODE (below)</th>
</tr>
</thead>
<tbody>
<tr>
<td>DTaP/IP/DTP/T1</td>
<td>SEP 05 2002</td>
<td></td>
<td>SNP</td>
<td>20022-27</td>
<td>07/07</td>
<td>LVL/RLVL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DTaP/IP/DTP/T2</td>
<td>NOV 08 2002</td>
<td></td>
<td>Aventis</td>
<td>CONVALENT</td>
<td>20022-27</td>
<td>07/07</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DTaP/IP/DTP/T3</td>
<td>OCT 09 2003</td>
<td></td>
<td>Aventis</td>
<td>CVA-1</td>
<td>12/06</td>
<td>LVL/RLVL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Polio 1</td>
<td>AUG 11 2006</td>
<td></td>
<td>Aventis</td>
<td>1038-88AA</td>
<td>05/10</td>
<td>LVL/RLVL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Td</td>
<td>LVL/RLVL</td>
<td></td>
<td>Aventis</td>
<td>1038-70</td>
<td>12/06</td>
<td>LVL/RLVL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Polio 2</td>
<td>NOV 08 2002</td>
<td></td>
<td>Aventis</td>
<td>100038</td>
<td>07/07</td>
<td>LVL/RLVL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Polio 3</td>
<td>JAN 09 2003</td>
<td></td>
<td>Aventis</td>
<td>100906</td>
<td>07/07</td>
<td>LVL/RLVL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Polio 4</td>
<td>AUG 11 2006</td>
<td></td>
<td>Aventis</td>
<td>100991</td>
<td>07/07</td>
<td>LVL/RLVL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MMR 1</td>
<td>JUL 11 2003</td>
<td></td>
<td>Merck</td>
<td>0602</td>
<td>07/07</td>
<td>LVL/RLVL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MMR 2</td>
<td>AUG 11 2006</td>
<td></td>
<td>Merck</td>
<td>0602</td>
<td>07/07</td>
<td>LVL/RLVL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HIB 1</td>
<td>SEP 05 2002</td>
<td></td>
<td>Merck</td>
<td>0283</td>
<td>07/07</td>
<td>LVL/RLVL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HIB 2</td>
<td>JAN 09 2003</td>
<td></td>
<td>Merck</td>
<td>0832</td>
<td>07/07</td>
<td>LVL/RLVL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HIB 3</td>
<td>JUL 11 2003</td>
<td></td>
<td>Merck</td>
<td>0832</td>
<td>07/07</td>
<td>LVL/RLVL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hep A 1</td>
<td>JUN 09 2009</td>
<td></td>
<td>Merck</td>
<td>1005</td>
<td>07/07</td>
<td>LVL/RLVL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hep A 2</td>
<td>LVL/RLVL</td>
<td></td>
<td>Merck</td>
<td>1005</td>
<td>07/07</td>
<td>LVL/RLVL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vaccine</td>
<td>Date</td>
<td>Provider Name</td>
<td>Date Read</td>
<td>Result</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>------------------</td>
<td>------------</td>
<td>-------------------</td>
<td>-----------</td>
<td>--------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diphtheria &amp; Tetanus &amp; Pertussis (DTP)</td>
<td>OCT 9 2003</td>
<td>X. Carroll</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rubella</td>
<td>AUG 1 2006</td>
<td>J. Brown</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Polio 1</td>
<td>SEP 5 2002</td>
<td>N. Johnson</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Polio 2</td>
<td>AUG 1 2006</td>
<td>J. Brown</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Polio 3</td>
<td>JUL 1 2003</td>
<td>K. Turner</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MMR</td>
<td>AUG 1 2006</td>
<td>J. Brown</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hib</td>
<td>SEP 5 2002</td>
<td>J. Brown</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Varicella 1</td>
<td>OCT 4 2003</td>
<td>J. Brown</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Varicella 2</td>
<td>AUG 1 2006</td>
<td>J. Brown</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pneumonia 1</td>
<td>SEP 5 2002</td>
<td>J. Brown</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pneumonia 2</td>
<td>NOV 1 2002</td>
<td>J. Brown</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pneumonia 3</td>
<td>JAN 1 2003</td>
<td>J. Brown</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pneumonia 4</td>
<td>OCT 4 2003</td>
<td>J. Brown</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Influenza 1</td>
<td>OCT 4 2003</td>
<td>J. Brown</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Influenza 2</td>
<td>OCT 1 2004</td>
<td>J. Brown</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

VACCINES FOR CHILDREN (VFC) CODES:
1 = Medicaid, 2 = Uninsured, 3 = Native American or Alaskan Native,
4 = Underinsured, 5 = HealthWave, 6 = Fully Insured.
Number of private practices using electronic systems (e.g., registries, EMRs) continues to increase

- Many private providers now enter data into a registry
  - mandated in some locales
- Increasing numbers of ambulatory care settings use a basic electronic medical record
  - Recent stimulus funding has encouraged more widespread adoption
  - Although not necessarily among pediatric practices since this is primarily Medicare driven with some accommodations for practice that attend Medicaid patients
Technology has moved toward 2-dimensional barcodes as the standard, in retail, airlines, etc.

Price of 2-dimensional readers have decreased
  - Can now be purchased for as low as $150

Manufacturers now have the ability to print NDC, lot number and expiration date on individual vials or syringes directly on the production line using 2D technology
  - Currently labels are pre-printed with NDC offline
Combination Vaccine Administration Concerns

When a vaccine has more than one vial that need to be combined for administration, there are special bar coding issues. Here are some suggestions:

▶ Each vial of the pair should be color coded and identifiable by distinct packaging that makes it clear that those vials SHOULD only be administered TOGETHER.

▶ Only one of the vials should have a 2D scannable bar code

▶ If one of the vials COULD be used as a stand alone vaccine for administration, it should have either NO 2D bar code in order to remind that this should never be administered as a stand alone vaccine or the 2D bar code must denote the combination vaccine.

84
Combination Vaccine Administration Concerns

It is the AAP committee’s very strong concern that:

► If there are two vials with two separate 2D bar codes, that many end users would inappropriately scan only one of the vials which would compromise the documentation – including inventory, VAERS reporting, registry reporting, billing, etc.

► If there are two barcodes and both are scanned, then scanning could compromise documentation particularly billing of vaccine administration codes to third party payers.

► We feel that these situations need to be considered on a case-by-case basis
Opportunities

- Provide more accurate reporting of vaccine information
  - VAERS 30% error rate: 13-22% missing lot numbers; 10-15% inaccurate lot numbers
    - Eliminate extra or outdated doses with more automated recording of information
    - Improve accurate notification in case of recall

- Save the federal government millions of dollars
  - Improve accountability of the Vaccines for Children Program vaccine usage
  - Redirect $26.4 million currently spent on phone-driven National Immunization Survey. This could be more accurate using registries
Our Goals for 2D Bar Codes

- Improve patient safety
- Reduce errors in record documentation
- Improve accuracy of reports regarding vaccine injuries [VAERS]
- Increase office efficiency
- Encourage use of vaccine registries
- Encourage use of EMRs
- Potentially save the federal government millions of dollars.
Conclusion

- We’ve made great progress.
- Despite this being “low hanging fruit” with general consensus, it still takes a while to implement.
  [Weniger’s publications are from 1994!!!]
- Involvement and agreement of stakeholders is critical.
- Our ongoing task will be to educate stakeholders including vaccine administrators, software vendors, and immunization registries.
Contact Information

- Elizabeth Sobczyk
  Manager, Immunization Initiatives
  American Academy of Pediatrics
  esobczyk@aap.org

- Edward N Zissman, MD, FAAP
  Altamonte Pediatric Associates
  ezissman@aap.org

- Special thanks to Kathy Cain, MD, FAAP and Jon Almquist, MD, FAAP of the AAP Committee
QUESTIONS?